Zacks Upgrades Alimera Sciences to “Buy” (ALIM)


Alimera Sciences (NASDAQ:ALIM) was upgraded by Zacks from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday. The firm currently has a $4.75 target price on the biopharmaceutical company’s stock. Zacks‘s price objective would indicate a potential upside of 12.03% from the company’s current price.

Zacks’ analyst wrote, “Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals.

Source :